Vistagen Therapeutics Inc VTGN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/28/24 EDT
5.55quote price arrow up+0.27 (+5.11%)
Volume
3,347
Close
5.28UNCH (UNCH)
Volume
1,232,200
52 week range
1.62 - 24.71
Loading...
  • Open4.59
  • Day High5.67
  • Day Low4.59
  • Prev Close4.57
  • 52 Week High24.71
  • 52 Week High Date08/07/23
  • 52 Week Low1.62
  • 52 Week Low Date06/26/23

Key Stats

  • Market Cap142.693M
  • Shares Out27.03M
  • 10 Day Average Volume0.22M
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change2.72

KEY STATS

  • Open4.59
  • Day High5.67
  • Day Low4.59
  • Prev Close4.57
  • 52 Week High24.71
  • 52 Week High Date08/07/23
  • 52 Week Low1.62
  • 52 Week Low Date06/26/23
  • Market Cap142.693M
  • Shares Out27.03M
  • 10 Day Average Volume0.22M
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change2.72

RATIOS/PROFITABILITY

  • EPS (TTM)-3.56
  • P/E (TTM)-1.48
  • Fwd P/E (NTM)-2.96
  • EBITDA (TTM)-33.773M
  • ROE (TTM)-44.55%
  • Revenue (TTM)1.042M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-3,076.62%
  • Debt To Equity (MRQ)0.01%

EVENTS

  • Earnings Date06/26/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vistagen Therapeutics Inc

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an...
Jon Saxe J.D.
Independent Chairman of the Board
Shawn Singh J.D.
Chief Executive Officer, Director
Joshua Prince
Chief Operating Officer
Cynthia Anderson CPA
Chief Financial Officer
Reid Adler J.D.
Chief Corporate Development Officer and General Counsel
Address
343 ALLERTON AVENUE
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
LTRN
Lantern Pharma Inc
8.80UNCHUNCH
IOBT
IO Biotech Inc
1.75UNCHUNCH
BCAB
Bioatla Inc
3.44UNCHUNCH
ANIX
Anixa Biosciences Inc
3.12UNCHUNCH
VINC
Vincerx Pharma Inc
5.06UNCHUNCH